美国Integrated Diagnostics
Integrated Diagnostics 正在开发基于血液的大规模分子诊断技术，该技术通过同时监测数十到数百个疾病标记物，实现重大疾病，如肺癌和阿尔茨海默氏症的早期检测。该公司由系统生物学先驱 Lee Hood 博士于 2009 年 10 月创立，公司正致力于通过采用尖端信息学技术进行生物标记物选择，以及采用创新的具有类似抗体特性的合成诊断和治疗剂——蛋白质催化的捕获剂，开发新一代个体化医疗解决方案。Integrated Diagnostics 的目标是开发用于严重疾病早期检测的新一代低成本、大规模诊断分析技术。该公司专注于从系统生物学角度研究包含蛋白质、基因及其他分子的疾病病理生理学分子网络。投资者包括 InterWest Partners、The Wellcome Trust 和 BioTechCube Luxembourg。基础知识产权由系统生物学研究所和加州理工学院独家授权。






Integrated Diagnostics is developing large-scale, blood-based molecular diagnostics that detect important diseases like lung cancer and Alzheimer's at their earliest stages by simultaneously monitoring tens to hundreds of disease markers. The company, founded in October 2009 by systems biology pioneerDr. Lee Hood, is creating a new generation of personalized medical solutions using sophisticated informatics for biomarker selection and a novel class of synthetically created diagnostic and therapeutic agents with antibody-like properties: protein-catalyzed capture agents. Integrated Diagnostics' mission is to build a new generation of low-cost, large-scale diagnostic assays for early detection of serious diseases. The company is conceptually based on a systems view of disease where pathophysiology arises from disease-perturbed networks of proteins, genes, and other molecules. Investors include InterWest Partners, The Wellcome Trust, and BioTechCube Luxembourg. Foundational intellectual property is exclusively licensed from the Institute of Systems Biology and Caltech.